LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $254,919 | $726,232 | $898,100 | $1.3M | $1.7M |
| Operating expenses | $5.1M | $3.6M | $5.1M | $6.3M | $6.7M |
| Operating income | -$5.1M | -$3.6M | -$5.1M | -$6.3M | -$6.7M |
| Interest expense | $9,158 | $16,821 | $16,233 | $8,875 | $7,414 |
| Income tax expense | $1,600 | — | — | — | — |
| Net income | -$6.1M | -$3.6M | -$5.1M | -$6.3M | -$6.7M |
| Balance Sheet | |||||
| Cash and equivalents | — | — | $4.2M | $5.4M | $4.8M |
| Current assets | $5.2M | $1.1M | $4.3M | $5.6M | $5.1M |
| Total assets | $12.7M | $1.1M | $4.3M | $5.6M | $5.1M |
| Current liabilities | $1.3M | $318,284 | $313,858 | $395,756 | $302,926 |
| Total liabilities | $1.8M | $318,284 | — | — | — |
| Stockholders' equity | $9.7M | $827,219 | $4.0M | $5.2M | $4.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$3.1M | -$3.2M | -$4.3M | -$4.6M | -$4.1M |
| Stock-based compensation | $1.4M | $418,422 | $773,203 | $1.5M | $2.6M |
Shares outstanding 12.4M · Free float 70.3%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.